Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | CCR8 | P51685 | 2/20 | 0.40 |
| ▸ | LPO | P22079 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7172386 | 0.98 | HTR2C (0.46) | HTR2CHTR2ABRD4KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7179318 | 0.98 | HTR2C (0.46) | HTR2CHTR2ABRD4KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7175653 | 0.98 | HTR2C (0.46) | HTR2CHTR2ABRD4KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7173179 | 0.98 | HTR2C (0.46) | HTR2CHTR2ABRD4KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7176249 | 0.98 | HTR2C (0.46) | HTR2CHTR2ABRD4KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7171164 | 0.98 | HTR2C (0.46) | HTR2CHTR2ABRD4KDM4EL3MBTL1 | |
| SCHEMBL4109690 | 0.90 | CCR1 (0.54) | HTR2CHTR2ABRD4KDM4EL3MBTL1 | |
| SCHEMBL12877216 | 0.87 | HTR2C (0.42) | HTR2CHTR2ABRD4KDM4EL3MBTL1 | |
| SCHEMBL5265171 | 0.87 | HTR2C (0.42) | HTR2CHTR2ABRD4KDM4EL3MBTL1 | |
| SCHEMBL12075550 | 0.84 | KDM4E (0.40) | HTR2CHTR2ABRD4KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116601303-A | Analyte sensor with metal-containing redox mediator and method of use thereof | 雅培糖尿病护理公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022147496-A1 | ANALYTE SENSORS WITH METAL-CONTAINING REDOX MEDIATORS AND METHODS OF USING THE SAME | ABBOTT DIABETES CARE INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20220202326-A1 | ANALYTE SENSORS WITH METAL-CONTAINING REDOX MEDIATORS AND METHODS OF USING THE SAME | ABBOTT DIABETES CARE INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-11233205-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190189939-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2019-06-20 | — | — | US | disclosed |
| EP-2920186-B1 | NOVEL GOLD(III) COMPLEXES CONTAINING N-HETEROCYCLIC CARBENE LIGAND, SYNTHESIS, AND THEIR APPLICATIONS IN CANCER TREATMENT AND THIOL DETECTION | UNIV HONG KONG (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-20180128767-A1 | Small Volume In Vitro Analyte Sensor | ABBOTT DIABETES CARE INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9891185-B2 | Small volume in vitro analyte sensor | ABBOTT DIABETES CARE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9662057-B2 | Integrated sample acquisition and analyte measurement method | ABBOTT DIABETES CARE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9559321-B2 | Metal complexes for use as dopants and other uses | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20040054267-A1 | Small volume in vitro analyte sensor | THERASENSE, INC. | 2004-03-18 | — | — | US | disclosed |
| US-20030199744-A1 | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator | THERASENSE, INC. (US) | 2003-10-23 | — | — | US | disclosed |
| US-6618934-B1 | Method of manufacturing small volume in vitro analyte sensor | THERASENSE, INC. | 2003-09-16 | — | — | US | disclosed |
| US-6592745-B1 | Analytical sensors for the detection of bioanalytes in a small volume sample; to monitor glucose in diabetic patients and lactate during critical care | THERASENSE, INC. | 2003-07-15 | — | — | US | disclosed |
| US-6591125-B1 | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator | THERASENSE, INC. | 2003-07-08 | — | — | US | disclosed |
| US-6461496-B1 | BLOOD GLUCOSE | THERASENSE, INC. | 2002-10-08 | — | — | US | disclosed |
| US-6338790-B1 | DETECTION OF BIOANALYTES IN A SMALL VOLUME SAMPLE; CONCENTRATION OF A BIOMOLECULE, SUCH AS GLUCOSE OR LACTATE, USING TECHNIQUES SUCH AS COULOMETRY, AMPEROMETRY, AND POTENTIOMETRY. AN ENZYME CAPABLE OF CATALYZING THE | THERASENSE, INC. | 2002-01-15 | — | — | US | disclosed |
| US-6299757-B1 | ANALYTICAL SENSORS FOR THE DETECTION OF BIOANALYTES; ESPECIALLY MONITORING GLUCOSE LEVELS IN DIABETIC PATIENTS | THERASENSE, INC. | 2001-10-09 | — | — | US | disclosed |
| EP-1119637-A1 | SMALL VOLUME $i(IN VITRO) ANALYTE SENSOR WITH DIFFUSIBLE OR NON-LEACHABLE REDOX MEDIATOR | Therasense, Inc. (US) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020626-A1 | SMALL VOLUME IN VITRO ANALYTE SENSOR WITH DIFFUSIBLE OR NON-LEACHABLE REDOX MEDIATOR | THERASENSE, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190189939-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSTC | HTR2C 3191/4885HTR2A 4017/4885BRD4 1525/4885 |
| US-20220202326-A1 | ANALYTE SENSORS WITH METAL-CONTAINING REDOX MEDIATORS AND METHODS OF USING THE SAME | GPX4, LPO, PRDX3 | HTR2C 4499/4885HTR2A 4076/4885BRD4 3355/4885 |
| US-11233205-B2 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, OSTC | HTR2C 3191/4885HTR2A 4017/4885BRD4 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.